HLA-G and neoplasm: Furthermore, Vδ2 γδT was used as an effector cell carrying the Nb‐CAR.BiTE construct to address the limitations of autologous CAR‐T and complement CAR‐T and BiTE therapies by facilitating CAR‐independent natural anti‐tumor activity when antigen expression is inadequate.[27] We identified the up‐regulation of PD‐L1 in residual tumors following HLA‐G Nb‐CAR‐γδT treatment in NOD/scid gamma (NSG) mice and the frequent pairing of PD‐L1 and HLA‐G expression in patient tumor lesions.